Study of a drug combo for people with relapsed AML
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with acute myeloid leukemia (AML) that has come back or hasn't responded to treatment, including those who have previously taken venetoclax. The goal is to see if this combo can help control the leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have AML that has come back or hasn't responded to treatment, or you have secondary AML that developed from a prior blood disorder (like MDS or MPN).
- You have already been treated with a venetoclax-containing regimen.
- Your overall health is fairly good (able to do light activities).
- Your liver and kidneys are working adequately.
- If you are able to become pregnant or have a partner who can, you agree to use effective birth control during treatment and for several months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—aclarubicin, azacitidine, and venetoclax—for people with acute myeloid leukemia (AML) who cannot have intensive chemotherapy, or whose leukemia has returned after treatment. The goal is to see if this combination helps control the leukemia with manageable side effects.
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
This trial tests whether adding a drug called venetoclax to the usual chemotherapy (CLAG) helps people whose acute myeloid leukemia (AML) has come back or not responded to treatment. It aims to see if the combination improves outcomes compared to chemotherapy alone.
This trial tests a combination of two drugs, venetoclax (a pill) and decitabine (given by IV), for people with AML that has not responded to initial treatment or has come back. The goal is to see if this combination can help control the leukemia again.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.